© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Pyxis Oncology, Inc. (PYXS) stock surged +2.33%, trading at $1.76 on NASDAQ, up from the previous close of $1.72. The stock opened at $1.70, fluctuating between $1.70 and $1.81 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 04, 2026 | 1.71 | 1.81 | 1.70 | 1.76 | 173.44K |
| Apr 30, 2026 | 1.65 | 1.75 | 1.62 | 1.70 | 283.39K |
| Apr 29, 2026 | 1.70 | 1.73 | 1.64 | 1.66 | 277.9K |
| Apr 28, 2026 | 1.76 | 1.87 | 1.68 | 1.70 | 295.67K |
| Apr 27, 2026 | 1.91 | 1.98 | 1.72 | 1.76 | 565.85K |
| Apr 23, 2026 | 1.89 | 1.91 | 1.71 | 1.71 | 251.63K |
| Apr 22, 2026 | 1.73 | 1.94 | 1.69 | 1.88 | 667.82K |
| Apr 21, 2026 | 1.70 | 1.73 | 1.64 | 1.71 | 207.75K |
| Apr 20, 2026 | 1.65 | 1.73 | 1.62 | 1.70 | 238.82K |
| Apr 17, 2026 | 1.72 | 1.75 | 1.65 | 1.66 | 327.27K |
| Apr 16, 2026 | 1.70 | 1.72 | 1.66 | 1.70 | 121.71K |
| Apr 14, 2026 | 1.72 | 1.84 | 1.69 | 1.70 | 576.44K |
| Apr 13, 2026 | 1.70 | 1.75 | 1.60 | 1.71 | 369.25K |
| Apr 10, 2026 | 1.61 | 1.74 | 1.60 | 1.70 | 719.52K |
| Apr 09, 2026 | 1.46 | 1.62 | 1.42 | 1.61 | 797.35K |
| Apr 08, 2026 | 1.48 | 1.51 | 1.42 | 1.47 | 197.03K |
| Apr 07, 2026 | 1.44 | 1.48 | 1.41 | 1.46 | 427.78K |
| Apr 06, 2026 | 1.48 | 1.53 | 1.43 | 1.45 | 230.72K |
| Apr 02, 2026 | 1.43 | 1.50 | 1.40 | 1.48 | 195.74K |
| Apr 01, 2026 | 1.45 | 1.55 | 1.45 | 1.47 | 197.37K |
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
| Employees | 44 |
| Beta | 1.42 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |